Ninlaro (Ixazomib Citrate)

Ixazomib, the active ingredient in Ninlaro, is a proteasome inhibitor presented as an oral tablet for use in adult patients with multiple myeloma. It works by targeting malignant plasma cells and is prescribed as part of combination therapy after prior treatment. It is indicated for patients who have received at least one prior therapy and is administered under medical supervision.

GNH USA supplies Ninlaro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. Our distribution network ensures consistent product quality and regulatory compliance across regions.

Ninlaro (ixazomib) is used in the treatment of hematologic malignancies, specifically multiple myeloma. - Multiple Myeloma (relapsed/refractory): used in combination with lenalidomide and dexamethasone to improve disease control after prior therapy. - Multiple Myeloma (maintenance): incorporated into ongoing regimens to prolong progression‑free survival in patients responding to initial treatment.

Ixazomib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: upset stomach and possible vomiting. - Diarrhea: loose stools that may lead to dehydration. - Fatigue: persistent tiredness affecting daily activities. - Thrombocytopenia: reduced platelet count increasing bleeding risk.

Serious or Rare Side Effects: - Neutropenia: severe drop in white blood cells, raising infection risk. - Pulmonary embolism: blood clot in the lungs that can be life‑threatening. - Cardiac failure: worsening heart function presenting with shortness of breath or edema.

When prescribing Ninlaro, clinicians should consider several safety measures to minimize risks. - Monitor blood counts: perform regular CBC tests to detect cytopenias early. - Assess infection risk: watch for fever or signs of infection, especially during neutropenia. - Evaluate cardiac function: obtain baseline ECG in patients with known heart disease. - Avoid strong CYP3A4 inhibitors: concurrent use may increase ixazomib exposure. - Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Ixazomib can interact with other medicines, affecting its concentration or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ixazomib plasma levels and increase toxicity. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug exposure and reduce efficacy. - Anticoagulants (e.g., warfarin): heightened bleeding risk due to thrombocytopenia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly increase ixazomib exposure. - Live vaccines: immunosuppression may reduce vaccine effectiveness; consider timing. - Other proteasome inhibitors: concurrent use can lead to additive toxicity; avoid combination.